Daiichi Sankyo and Merck’s, known as MSD outside of the United States and Canada, Biologics License Application (BLA) for ifinatamab deruxtecan (I-DXd) has been accepted and granted Priority Review by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results